ArticleJournal of translational medicine2026
Longitudinal spatial multi-omics delineates tumor microenvironment remodeling across sequential EGFR-TKIs in EGFR-mutant NSCLC.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResistance to therapy is a frequent occurrence in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) who are treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, spatial information on how the tumor microenvironment (TME) changes within the same patient from baseline to resistance to first- and then third-generation EGFR-TKIs is scarce. Here, we used rare consecutive re-biopsy samples to build an exploratory, longitudinal, and spatially resolved atlas, aiming to describe within-patient TME remodeling patterns as a resource for hypothesis generation.
methodsA patient-matched cohort with serial samples obtained at baseline (T0), after first-generation EGFR-TKI resistance (T1), and after third-generation EGFR- TKI resistance (T2) was established. Using GeoMx Digital Spatial Profiling (DSP), tumor-enriched and stroma-enriched areas of interest (AOIs) were segmented, and paired RNA and protein profiles were quantified. We tracked temporal changes in compartment-specific heterogeneity and immune remodeling and explored associations between early remodeling and subsequent T790M acquisition.
resultsWe analyzed the data from 15 samples of 6 patients. Tumor- and stroma-enriched compartments were not only transcriptionally but also protein-wise consistently distinct. Spatial heterogeneity was relatively stable from T0 to T1 but increased from T1 to T2, with changes in the stroma-enriched compartments accounting for most of the increase. Early remodeling featured loss of T cell activation programs, reduced neutrophil signatures, increased myeloid remodeling, and impairment of antigen presentation. Longitudinal analyses suggested a biphasic immune trajectory, with early myeloid remodeling and late stromal checkpoint reprogramming. Early spatial remodeling patterns showed potential differences between samples that later acquired T790M and those that did not.
conclusionsThis study provides preliminary evidence for dynamic TME changes during sequential EGFR-TKI therapy in EGFR-mutant NSCLC. It suggests a late, stroma-associated expansion of spatial heterogeneity and stage-dependent immune remodeling. Additionally, it offers an initial spatial atlas and generates testable, time-aware hypotheses for future validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.